Virax Biolabs Group Limited VRAX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -87.75%
- 1 year
- -92.18%
- Market cap
- 1.43M
- Revenue (ttm)
- 156.42K
- EPS (ttm)
- -12.64
- Shares out
- 4.34M
- Forward P/E
- -1.01
- YTD return
- -87.75%
- 1-year return
- -92.18%
- Volume
- 33.72K
- Avg volume
- 382.97K
- Open
- 1.09
- Previous close
- 1.14
- Day's range
- 1.04 – 1.18
- 52-week range
- 1.04 – 21.75
- Beta
- 1.93
2Y -49.90 (-97.84%)
Key statistics
- Enterprise value
- 1.17M
- PEG ratio
- 0.00
- Price / sales
- 53.30
- Price / book
- 0.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 2752.20%
- Free cash flow
- -4.99M
- Total cash
- 3.67M
- Total debt
- 224.30K
- Return on equity
- -95.98%
- Short % of float
- 11.01%
- 50-day average
- 1.92
- 200-day average
- 1.66
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- viraxbiolabs.com
News
Virax Biolabs Enter Agreements With Three Chinese Distributors For Its ImmuneSelect Research-Use Immune Profiling Products 
Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Decline in Short Interest 
12 Health Care Stocks Moving In Monday's After-Market Session 
12 Health Care Stocks Moving In Wednesday's After-Market Session - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Virax Biolabs Management Believes Current Valuation Doesn't Fully Reflect Its Audited Financial Position, Clinical And Development Programs, Commercial Progress Or Strategic Assets
Your note
Sign in to keep a note on VRAX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 4.50% | 145,400 | 279.17K | Sep 29, 2024 |
| Squarepoint Ops LLC | 1.26% | 40,620 | 77.99K | Sep 29, 2024 |
| UBS Group AG | 0.64% | 20,530 | 39.42K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.36% | 11,635 | 22.34K | Sep 29, 2024 |
| Headlands Technologies LLC | 0.01% | 185 | 355 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.02% | 542 | 1.04K | Oct 30, 2024 |